Revolution Medicines announced a webcast on May 31 to discuss positive Phase 3 results from their RASolute 302 trial, which tested daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The data will be presented at the 2026 ASCO Annual Meeting's Plenary Session. This trial showed unprecedented survival benefits, highlighting daraxonrasib's potential as a targeted therapy for RAS-addicted cancers. Investors and the public can access the live and archived webcast on the company's website.
In 2026, Alphabet has delivered outstanding returns over one, three, and five years, contrasting with struggles faced by other hyperscalers. The semiconductor sector remains highly cyclical, impacting both business performance and stock prices. A com...
IES Holdings has been upgraded to a Buy rating due to a record backlog increase of 63% to $3.9 billion and ongoing capacity expansion. The company’s Communications and Infrastructure Solutions segments, which have higher margins and growth potential,...
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
